Arca Biopharma (ABIO) Announces rNAPc2 COVID-19 Patent Assignment Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P, Nasdaq futures slip as markets await Iran sanctions, Nvidia results
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement
July 7, 2021 8:00 AM EDTProvides exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID-19 and other indications
WESTMINSTER, Colo., July 07, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced it has entered into a patent assignment agreement with the... More
